Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 29 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/8/2008 First Published: 3/24/2003


1.		Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				NSABP-R-04 NCT00058474, NSABP-R-04, CALGB-NSABP-R-04

Last Modified: 10/10/2008 First Published: 3/13/2006


2.		Phase III Randomized Study of Adjuvant Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients Who Have Undergone Surgery and Neoadjuvant Chemoradiotherapy for Stage II or III Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				ECOG-E5204 E5204, NSABP-ECOG-E5204, NCCTG-ECOG-E5204, NCT00303628


3.		Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				05-345 NCT00307736


4.		Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2007-0080 NCT00543842

Last Modified: 10/2/2008 First Published: 9/16/2008


5.		Phase I/II Randomized Study of Erlotinib Hydrochloride in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci in Patients With Curatively Treated Stage I-III Colorectal Cancer or Adenoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Not specified				NCI				UCIRVINE-UCI06-8-01 UCI06-8-01, NCT00754494


6.		Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				HOG GI03-53 NCT00216086


7.		Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				3304C NCT00250835

Last Modified: 9/29/2008 First Published: 2/3/2006


8.		Phase II Study of Neoadjuvant Chemoradiotherapy Comprising Radiotherapy and Fluorouracil With or Without Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Followed By Surgical Resection in Patients With Stage II or III Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				UCSF-03451 UCSF-H44287-23127-03, NCT00335816, UMN-2003UC036


9.		5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage I/II Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				SCRI GI 65 AVF3105s, NCT00308516


10.		Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				803437 UPCC 09204, NCT00353457

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute